Clinical Trial Update: Baricitinib for Respiratory Injury in Patients With Intracerebral Hemorrhage [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating baricitinib for respiratory injury in patients with intracerebral hemorrhage has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intracerebral Hemorrhage
• Lung Injury

Drugs mentioned

• Olumiant (baricitinib)

Snippet

Sponsor: De-zhi Kang | Conditions: Intracerebral Hemorrhage, Acute Lung Injury(ALI) | Phase 2 | Status: COMPLETED